Mutation Patterns in Portuguese Families with Hereditary Breast and Ovarian Cancer Syndrome

被引:3
|
作者
Vicente, Rodrigo [1 ]
Costa, Diogo Alpuim [2 ,3 ]
Vitorino, Marina [1 ]
Mendes, Ana Duarte [1 ]
Santos, Catarina [1 ]
Fontes-Sousa, Mario [2 ]
机构
[1] Hosp Prof Doutor Fernando Fonseca, Med Oncol Dept, IC19 276, P-2720276 Amadora, Portugal
[2] CUF Oncol, Breast Canc Unit, P-1998018 Lisbon, Portugal
[3] NOVA Med Sch, Fac Ciencias Med, P-1169056 Lisbon, Portugal
关键词
hereditary breast and ovarian cancer syndrome; breast cancer; ovarian cancer; founder mutations; Portuguese families; genetic testing; BRCA2; MUTATIONS; RISK; CARRIERS; REARRANGEMENT; BRCA1/BRCA2; SURVIVAL; OLAPARIB; SURGERY;
D O I
10.3390/cancers14194717
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary The pattern of Breast Cancer Genes 1 (BRCA1) and 2 (BRCA2) mutations in Hereditary Breast Ovarian Cancer (HBOC) families varies widely among different populations. About 30% of Portuguese HBOC can be associated with inherited cancer caused by BRCA1 or BRCA2 mutations. Three variants were identified (c.156_157insAlu in the BRCA2 gene and c.3331_3334del and c.2037delinsCC in the BRCA1 gene), accounting for about 50% of all Portuguese pathogenic mutations. Characterising the mutational spectrum in specific populations allows for a more efficient and cost-saving screening approach. Germline pathogenic variants in the Breast Cancer Genes 1 (BRCA1) and 2 (BRCA2) are responsible for Hereditary Breast and Ovarian Cancer (HBOC) syndrome. Genetic susceptibility to breast cancer accounts for 5-10% of all cases, phenotypically presenting with characteristics such as an autosomal dominant inheritance pattern, earlier age of onset, bilateral tumours, male breast cancer, and ovarian tumours, among others. BRCA2 pathogenic variant is usually associated with other cancers such as melanoma, prostate, and pancreatic cancers. Many rearrangements of different mutations were found in both genes, with some ethnic groups having higher frequencies of specific mutations due to founder effects. Despite the heterogeneity of germline BRCA1/BRCA2 mutations in Portuguese breast or/and ovarian cancer families, the first described founder mutation in the BRCA2 gene (c.156_157insAlu) and two other variants in the BRCA1 gene (c.3331_3334del and c.2037delinsCC) contribute to about 50% of all pathogenic mutations. Furthermore, the families with the BRCA1 c.3331_3334del or the c.2037delinsCC mutations share a common haplotype, suggesting that these may also be founder mutations in the Portuguese population. Identifying specific and recurrent/founder mutations plays an important role in increasing the efficiency of genetic testing since it allows the use of more specific, cheaper and faster strategies to screen HBOC families. Therefore, this review aims to describe the mutational rearrangements of founder mutations and evaluate their impact on the genetic testing criteria for HBOC families of Portuguese ancestry.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Germline EMSY sequence alterations in hereditary breast cancer and ovarian cancer families
    Maatta, Kirsi M.
    Nurminen, Riikka
    Kankuri-Tammilehto, Minna
    Kallioniemi, Anne
    Laasanen, Satu-Leena
    Schleutker, Johanna
    BMC CANCER, 2017, 17
  • [2] Hereditary Breast-Ovarian Cancer Syndrome in Russia
    Sokolenko, A. P.
    Iyevleva, A. G.
    Mitiushkina, N. V.
    Suspitsin, E. N.
    Preobrazhenskaya, E. V.
    Kuligina, E. Sh.
    Voskresenskiy, D. A.
    Lobeiko, O. S.
    Krylova, N. Yu.
    Gorodnova, T. V.
    Buslov, K. G.
    Bit-Sava, E. M.
    Dolmatov, G. D.
    Porhanova, N. V.
    Polyakov, I. S.
    Abysheva, S. N.
    Katanugina, A. S.
    Baholdin, D. V.
    Yanus, G. A.
    Togo, A. V.
    Moiseyenko, V. M.
    Maximov, S. Ya.
    Semiglazov, V. F.
    Imyanitov, E. N.
    ACTA NATURAE, 2010, 2 (04): : 31 - 35
  • [3] An Overview of Hereditary Breast and Ovarian Cancer Syndrome
    Smith, Edith Caroline
    JOURNAL OF MIDWIFERY & WOMENS HEALTH, 2012, 57 (06) : 577 - 584
  • [4] A case of simultaneous breast cancer and ovarian cancer based on a hereditary breast and ovarian cancer syndrome
    Kotaka, Saki
    Yasui, Hiroaki
    Tsubouchi, Hirofumi
    Mori, Masahiko
    Kotani, Haruru
    Yoshimura, Akiyo
    Ouchi, Akira
    Okuno, Masataka
    Komori, Koji
    Shimizu, Yasuhiro
    Suzuki, Shiro
    NAGOYA JOURNAL OF MEDICAL SCIENCE, 2023, 85 (04): : 814 - 821
  • [5] Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia
    Konecny, Michal
    Milly, Miriam
    Zavodna, Katarina
    Weismanova, Eva
    Gregorova, Jaroslava
    Mlkva, Iveta
    Ilencikova, Denisa
    Kausitz, Juraj
    Bartosova, Zdena
    BREAST CANCER RESEARCH AND TREATMENT, 2011, 126 (01) : 119 - 130
  • [6] The role of targeted BRCA1/BRCA2 mutation analysis in hereditary breast/ovarian cancer families of Portuguese ancestry
    Peixoto, A.
    Santos, C.
    Pinto, P.
    Pinheiro, M.
    Rocha, P.
    Pinto, C.
    Bizarro, S.
    Veiga, I.
    Principe, A. S.
    Maia, S.
    Castro, F.
    Couto, R.
    Gouveia, A.
    Teixeira, M. R.
    CLINICAL GENETICS, 2015, 88 (01) : 41 - 48
  • [7] Screening of HELQ in breast and ovarian cancer families
    Pelttari, Liisa M.
    Kinnunen, Laura
    Kiiski, Johanna I.
    Khan, Sofia
    Blomqvist, Carl
    Aittomaki, Kristiina
    Nevanlinna, Heli
    FAMILIAL CANCER, 2016, 15 (01) : 19 - 23
  • [8] Hereditary breast and ovarian cancer syndrome: Considering the complexities
    Senter, Leigha
    CURRENT PROBLEMS IN CANCER, 2014, 38 (06) : 226 - 234
  • [9] Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age
    van der Kolk, Dorina M.
    de Bock, Geertruida H.
    Leegte, Beike K.
    Schaapveld, Michael
    Mourits, Marian J. E.
    de Vries, Jakob
    van der Hout, Annemieke H.
    Oosterwijk, Jan C.
    BREAST CANCER RESEARCH AND TREATMENT, 2010, 124 (03) : 643 - 651
  • [10] Germline EMSY sequence alterations in hereditary breast cancer and ovarian cancer families
    Kirsi M. Määttä
    Riikka Nurminen
    Minna Kankuri-Tammilehto
    Anne Kallioniemi
    Satu-Leena Laasanen
    Johanna Schleutker
    BMC Cancer, 17